Genmab

	15/10 09:30 af E L	New trial: A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (link)
	15/10 09:20 af E L	just checked we have to wait till oct27 for Novartis Q3 to get the first glimpse
	15/10 09:17 af Solsen	Ja Ocrevus er vild. Også spændende hvad Novartis kan gøre ved Roche.
	15/10 09:16 af Solsen	Mange patienter kun behandlet kort tid og flere med meget små doser.
	15/10 09:16 af Solsen	Det var spændende data på GEN1046, men vi må vente med at se hvor gode de egentlig er. Mange ots kun behandlet e
	15/10 09:14 af Bulder	;-)
	15/10 09:08 af E L	and Society for Immunotherapy of Cancer @sitcancer suddenly started following me on twitter; they are on to me ! :-D
	15/10 09:06 af E L	exactly lol. the links also don't work anymore
	15/10 09:03 af Sukkeralf	I was also wondering about that because it should have been at late last night at kl 23 and only titles
	15/10 08:59 af E L	It appears we had a real scoop here yesterday with those SITC abstracts... I was already surprised they were hours early, and even more surprised we could see the content... it seems to have been a mistake lol
	15/10 08:53 af Helge Larsen/PI-redaktør	Tak Sukker. Det er imponerende.
	15/10 08:42 af Sukkeralf	Ocrevus begynder at ligne et 5 milliard dollar drug - bare GSK i sin tid havde sat mere fart over feltet :-(
	15/10 08:41 af Sukkeralf	(link)
	15/10 08:40 af Sukkeralf	Lad os håbe Novartis begynder at tage markedsandele med Kesimpta, for Ocrevus kører bare derudaf: Roche Q3 sales for Ocrevus: CHF 1.2 billion, up 37%
	15/10 08:20 af Helge Larsen/PI-redaktør	Genmab @Genmab We’re excited to share updates from Genmab’s pipeline at the virtual #SITC2020, including first-in-human data on a bispecific antibody in joint development with (link)
	15/10 07:36 af transalp	Go morgen.. :)
	15/10 02:27 af SEACOP	(link)
	15/10 02:27 af SEACOP	Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting.
	14/10 16:42 af E L	well , 50/50 seems to be Jan's favourite number, so who knows ;-) And I can't really remember him mentioning the number 0 :-D
	14/10 16:33 af Solsen	I belive it would be worth trying to make a 50/50 collaboration with ADC. The abstract from solid cancers are very exciting in my view.
	14/10 16:29 af troldmanden	Aftalen skal i hvert fald laves signifikant om hvis Genmab skal smide flere penge efter stoffet. Jeg hælder til Genmab smider de 25%. Mod et lille upfront beløb og så måske 10-25% af ADC fremtidige potentielle royalties. Der skal alligevel en big pharma med ind over for at marekdesføre
	14/10 16:23 af Bulder	What are the posibilities? Buying another 25% or selling the 25%?
	14/10 16:16 af Solsen	ADC just raised +$200 mln. Perhaps some of them will go to Genmab ;-)
	14/10 16:12 af E L	that is all I know. I assume they are still talking ;-)

	14/10 16:12 af E L	"Our collaboration and license agreement with Genmab may require a divestment of Cami, in which Genmab has a 25% interest. On June 24, 2020, we and Genmab agreed to enter into a period of good faith negotiations regarding the key financial terms of our license agreement."
	14/10 15:56 af Bulder	when was the deadline?
	14/10 15:50 af E L	Yes, i am also really curious. The good thing is that Genmab can choose from strength. If they choose not to pursue it, it will not be such a big deal, as they have plenty of other stuff in their pipeline, probably more than they can handle at the moment. So we know that if they do choose to pursue it, we can be reasonably optimistic it can be successfull
	14/10 15:35 af Solsen	Cami still looks interesting and now in solid cancer. Wonder what Genmab will do ?
	14/10 14:48 af E L	“These findings indicate this medication can provide relief at least a year after the last dose, including improvements in proptosis and diplopia, which are especially difficult symptoms to manage,”
	14/10 14:46 af E L	TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED) 10/14/20 (link)
	14/10 14:02 af bongobob	Fantastiske nyheder både Amivantamab og PD-L1x4-1BB. Duobody validated
	14/10 13:56 af Bulder	Tak bongo. Så amivantamab 100% RR i første linje (få pts ganske vist) og godkendelse om et par år.
	14/10 13:46 af Plimsoller	Tak Helge. Projekteret i den øveste del af intervallet. Hvis det ender sådan, så kan vi ikke klage :-)
	14/10 13:08 af E L	SITC ID: 621 A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers (link) (camidanlumab tesirine (ADCT-301))
	14/10 12:58 af E L	SITC ID: 617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death (link)
	14/10 12:53 af Helge Larsen/PI-redaktør	Opdaterede salgstal på Darzalex. (link)
	14/10 12:51 af E L	SITC ID: 704 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models (link)
	14/10 12:46 af E L	Disease control, including stable disease at first assessment and partial responses in triple-negative breast cancer, ovarian cancer, and immune checkpoint inhibitor (ICI)–pretreated NSCLC, occurred in 40/61 patients (65.6%).
	14/10 12:45 af E L	Conclusions DuoBody-PD-L1×4-1BB demonstrated biologic activity and a manageable safety profile. Encouraging early clinical activity across different dose levels was observed in a heavily pretreated population with advanced solid tumors, including those resistant to prior immunotherapy or typically less sensitive to ICIs. Expansion cohorts of patients for whom DuoBody-PD-L1×4-1BB treatment could be relevant and biologically sound have started enrollment. Updated data will be presented.
	14/10 12:43 af GeorgeBest	12:40 I like the phrase “superior”
	14/10 12:41 af E L	SITC ID: 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in patients with advanced solid tumors (link)
	14/10 12:41 af GeorgeBest	Thanks E L and bongobob
	14/10 12:40 af E L	SITC ID: 561 DuoBody®-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation (link)
	14/10 12:37 af bongobob	Meget informativt om Amivantamab. 6-12 md approval...moving to 1.line... Beklager hvis den har været linket. (link)
	14/10 11:42 af Sukkeralf	Its going to be fun to see milestones for filing and approval to get a feeling about how backloaded these Duobody deals are
	14/10 11:40 af Bulder	I didn't realize we were that close to an amivantamab filing.
	14/10 11:19 af Bulder	Thx E L
	14/10 11:12 af Sukkeralf	10:50 E L - ohh yes sorry !
	14/10 11:04 af E L	Beyond that i can only find JNJ-7957 (BCMA/CD3), JNJ-7564 (GPRC5D/CD3) for planned filing 2020-2023
	14/10 11:03 af E L	I think 10:50 points to amivantamab filing in Q4?